# AstraZeneca completes transfer of its global rights to Eklira and Duaklir to Covis Pharma

- Link: https://www.directorstalkinterviews.com/astrazeneca-completes-transfer-of-its-global-rights-to-eklira-and-duaklir-to-covis-pharma/4121040713
- Published: 2022-01-05T07:16:08+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has completed the transfer of its global rights to _Eklira_ (aclidinium bromide),
known as _Tudorza_ in the US, and _Duaklir_ (aclidinium bromide/formoterol) to Covis
Pharma Group (Covis Pharma).

**Financial considerations**

Under the terms of the agreement, AstraZeneca received a payment of $270m from Covis
Pharma. AstraZeneca will also receive payments in respect of certain ongoing development
costs related to the medicines. The income arising from the upfront payment will
be fully offset by a charge for derecognition of the associated intangible asset
and therefore no Other Operating Income will be recognised in AstraZeneca’s financial
statements.

**Notes**

**_Eklira_** **and _Duaklir_**

_Eklira_ (aclidinium bromide) and _Duaklir_ (aclidinium bromide/formoterol) are 
inhaled respiratory medicines used for the maintenance treatment of chronic obstructive
pulmonary disease. _Eklira_ is a long-acting muscarinic antagonist (LAMA), which
is marketed in the US as _Tudorza_ and in some countries as _Bretaris_.

_Duaklir_ is a combination therapy that contains both a LAMA and a long-acting beta2-
agonist (LABA). It is marketed in some countries as _Brimica_.

Both medicines are presented as a dry powder for inhalation and are delivered via
a breath-actuated multi-dose dry powder inhaler, _Genuair_ (_Pressair_ in the US_)_.
AstraZeneca licensed the global rights to both products from Almirall S.A. in 2014.

**AstraZeneca**

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company
that focuses on the discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular,
Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca
operates in over 100 countries and its innovative medicines are used by millions
of patients worldwide. Please visit [astrazeneca.com](https://www.astrazeneca.com/)
and follow the Company on Twitter [@AstraZeneca](https://twitter.com/AstraZeneca).

Share on: